alexa The Role of Bivalirudin in Percutaneous Coronary Intervention | OMICS International
ISSN: 2329-6607
Cardiovascular Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Role of Bivalirudin in Percutaneous Coronary Intervention

Mohamed Effat* and Said Alsidawi

Division of Cardiovascular Health and Disease, University of Cincinnati, USA

*Corresponding Author:
Mohamed Effat
Division of Cardiovascular Health and Disease
University of Cincinnati, USA
Tel: 513-558-4306
E-mail: [email protected]

Received date: December 04, 2013; Accepted date: December 07, 2013; Published date: December 14, 2013

Citation: Effat M, Alsidawi S (2013) The Role of Bivalirudin in Percutaneous Coronary Intervention. Cardiol Pharmacol 2:e120. doi:10.4172/2329-6607.1000e120

Copyright: © 2013 Effat M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Cardiovascular Pharmacology: Open Access

Bivalirudin (angiomax) is a reversible direct thrombin inhibitor. It is a polypeptide that has a carboxy-terminal region that recognizes thrombin’s fibrinogen-binding site, and an amino-terminal tetrapeptide that inhibits the active site of thrombin. It is considered superior to its prototype; hirudin as it is less dependent on renal function and has a lower incidence of anaphylaxis. Bivalirudin has a half-life of 25 minutes and is primarily eliminated via proteolytic cleavage. Compared to heparin, direct thrombin inhibitors, such as bivalirudin, exhibit less variable level of anticoagulation, and they inactivate both free as well as fibrin-bound thrombin. [1]

In most cardiac catheterization laboratories across the United States, Bivalirudin is used mainly as a heparin substitute such as in patients intolerant to heparin (e.g. history of HIT syndrome). However, Bivalirudin clinical studies have demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). This therapy has also gained class I recommendation from the ACC/AHA updated guidelines for all of the above mentioned conditions. [2,3]

The Bivalirudin Angioplasty Trial (BAT) was a randomized, doubleblinded, multi-center trial that included 4098 patients undergoing PCI for unstable angina. In this trial, the composite endpoint of death, MI or revascularization was lower in the bivalirudin arm at 90 days with absolute benefits being sustained through 180 days. There was also a significant reduction in the rate of bleeding in the bivalirudin arm compared to heparin. [4]

Similarly, the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-1 trial evaluated the efficacy of bivalirudin relative to heparin in patients undergoing PCI. Glycoprotein (GP) IIB/IIIA inhibitors were used in 72 % of patient and clopidogrel was used in 56% of patients. The incidence of composite end point of death, myocardial infarction, or repeat revascularization was no significantly different between the bivalirudin and heparin groups (5.6% and 6.9% respectively, p = 0.40). Major bleeding occurred in 2.1% versus 2.7% of patients randomized to bivalirudin or heparin, respectively (p = 0.52). [5]

In the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial, patients were assigned to either bivalirudin, with provisional use of GP IIb/IIIa inhibitor or low-dose unfractionated heparin (UFH) plus planned GP IIb/IIIa inhibitor. There was similar rate of 30-day primary composite endpoint of death, MI, urgent revascularization, and in-hospital major bleeding between the bivalirudin and the heparin-GP IIb/IIIa groups. [6] However, bivalirudin led to significantly less in-hospital major bleeding when compared to the heparin-GP IIb/IIIa inhibitor combination (2.4% versus 4.1%, p < 0.001). There was a difference in mortality favoring bivalirudin at 30 days and 6 months, and 12 months.

Higher risk patients with UA/NSTEMI who were considered for an early invasive strategy were evaluated in the Bivalirudin for Patients with Acute Coronary Syndromes-(Acuity Trial). In this pivotal trial, 13,819 patients were assigned to one of three anti-thrombotic regimens: unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin alone. The rates of 30 day ischemic outcomes were similar between bivalirudin plus GP IIb/IIIa inhibitor compared with heparin plus GP IIb/IIIa inhibitor (7.7% and 7.3%, respectively). There were also similar rates of major bleeding (5.3% and 5.7%). As compared with heparin plus GP IIb/IIIa inhibitor, bivalirudin, alone, led to noninferior rates of ischemia (7.8% and 7.3%, respectively; P=0.32), and significantly reduced major bleeding (3.0% vs. 5.7%; P<0.001). [7]

Bivalirudin also underwent evaluation in the setting of STEMI patients. In the Bivalirudin during Primary PCI in Acute Myocardial Infarction- (HORIZONS-AMI trial) [8]. This was a multicenter trial that enrolled 3602 patients with ST-segment elevation myocardial infarction who were undergoing primary PCI. The patients were randomized to a regimen of heparin plus a GP IIb/IIIa inhibitor versus bivalirudin alone. Treatment with bivalirudin alone, as compared with heparin plus GP IIb/IIIa inhibitors was associated with a significant reduction in the 30-day primary endpoint of net adverse clinical events which was predominantly driven by a lower rate of major bleeding. It also lowered 30-day rates of death from cardiac causes (1.8% vs. 2.9% P=0.03) as well as death from all causes (2.1% vs. 3.1% P=0.047). Follow up at one, two, and three years showed that the reduction in the incidence of net adverse clinical events and major bleeding was robustly maintained in the bivalirudin monotherapy group. [8]


Bivalirudin represents an attractive option as an antithrombotic agent in the cardiac catheterization laboratory. It has several advantages over heparin, and based upon evidence from many clinical trials, it has been proven to be safer than and at least as effective as heparin in the STEMI, NSTEMI/UA, and elective PCI population. We expect that the use of this agent as an antithrombotic therapy during PCI will continue to gain traction in the next few years.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 3rd International Conference on Cardiovascular Medicine and Cardiac Surgery
    July 05-06, 2018 Berlin, Germany
  • 25th Annual Congress on Cardiology and Medical Interventions
    July 16-17, 2018 Atlanta, USA
  • 6th Global Experts Meeting on Cardiology and Cardiovascular Pharmacology
    September 24-25, 2018 Tokyo, Japan
  • Current and Future trends in Cardio Vascular Diseases: Research and Outcomes
    October 05-06, 2018 Los Angeles, USA

Article Usage

  • Total views: 12381
  • [From(publication date):
    December-2013 - Jun 24, 2018]
  • Breakdown by view type
  • HTML page views : 8538
  • PDF downloads : 3843

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7